CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors.
CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors.
复制标题
DOI：
10.1080/2162402x.2016.1203498
复制
发表时间：
2016-08
期刊：
影响因子：
7.2
通讯作者：
Umana P
中科院分区：
文献类型：
--
作者：
Bacac M;Klein C;Umana P
癌胚抗原 T 细胞双特异性抗体 (CEA TCB) 是一种双特异性抗体，用于通过新型分子形式 (2:1) 识别 CEA 和 CD3e，诱导 T 细胞介导的对 CEA 过表达肿瘤的杀伤，同时保留低 CEA 表达的原代细胞。 CEA TCB 治疗可抑制肿瘤生长并产生高度炎症的肿瘤微环境。
Carcinoembryonic antigen T cell bispecific antibody (CEA TCB) is a bispecific antibody used to recognize CEA and CD3e via a novel molecular format (2:1) that induces T cell-mediated killing of CEA over-expressing tumors while sparing primary cells with low CEA expression. CEA TCB treatment inhibits tumor growth and generates a highly inflamed tumor microenvironment.